1 Erratum to: Clin Drug Investig DOI 10.1007/s40261-016-0428-5
In the original publication, some errors are found and the following corrections should be noted:
Section 4, 4th paragraph, 1st sentence, which previously read:
The lower sunitinib hepatic exposure in female mice may anticipate both, the lesser susceptibility to toxicity observed of male patients [32], and the higher incidence (p = 0.016) of ≥3 grade adverse events [14, 15] and risk (p = 0.04) of thrombocytopenia [16] in female patients.
Should read:
The lower sunitinib hepatic exposure in male mice may anticipate both, the lesser susceptibility to toxicity observed of male patients [32], and the higher incidence (p = 0.016) of ≥3 grade adverse events [14, 15] and risk (p = 0.04) of thrombocytopenia [16] in female patients.
Section 4.1, 1st paragraph, 4th sentence, which previously read:
In fact, 32 % of patients discontinued sunitinib treatment because of a lack of efficacy [35] and this percentage increased to 49 % in the main clinical trial [24].
Should read:
In fact, 32 % of patients discontinued sunitinib treatment because of a lack of efficacy [35] and this percentage increased to 39 % in the main clinical trial [24].
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40261-016-0428-5.
Rights and permissions
About this article
Cite this article
Segarra, I., Modamio, P., Fernández, C. et al. Erratum to: Sunitinib Possible Sex-Divergent Therapeutic Outcomes. Clin Drug Investig 36, 863 (2016). https://doi.org/10.1007/s40261-016-0450-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-016-0450-7